| Schedule of segment significant expenses |
| | | | | | | | | | | | | | | | Three months ended June 30, | | | Six months ended June 30, | (in thousands) | | 2026 | | 2025 | | | 2026 | | 2025 | Revenue | | $ | 559 | | $ | — | | | $ | 797 | | $ | — | | | | | | | | | | | | | | | Less: | | | | | | | | | | | | | | Cost of product sales | | | 32 | | | — | | | | 46 | | | — | Research and development, net of tax credits, excluding share-based compensation | | | 3,134 | | | 3,302 | | | | 5,984 | | | 7,850 | General and administrative, excluding share-based compensation | | | 5,055 | | | 3,036 | | | | 9,241 | | | 7,465 | Commercial, excluding share-based compensation | | | 14,540 | | | 3,310 | | | | 28,308 | | | 11,335 | Medical affairs, excluding share-based compensation | | | 2,090 | | | 1,575 | | | | 3,891 | | | 3,745 | Share-based compensation expense | | | 1,338 | | | 1,308 | | | | 2,620 | | | 2,659 | Interest income | | | (1,741) | | | (516) | | | | (3,473) | | | (1,213) | Royalty financing interest expense | | | 3,705 | | | — | | | | 6,838 | | | — | Note payable interest expense | | | 1,020 | | | 951 | | | | 2,022 | | | 1,886 | Net loss | | $ | (28,614) | | $ | (12,966) | | | $ | (54,680) | | $ | (33,727) |
|